RxDoctor Payments DataLook up a doctor →

Angel Johnson, MD

Gynecology · New York, MANPI 1194005934

Payments from drug & device makers

$63,137in general payments, 2019–2025

Across 502 payments — averaging $125.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$43K
  • Boston Scientific$11K
  • Medtronic$1K
  • Coloplast$1K
  • Applied Medical Resources Corporation$902
  • Astellas Pharma US Inc$649
  • plus $6K from 52 others

What the payments were for

  • Consulting fees$43,94870%
  • Speaking & faculty fees$6461%
  • Travel & lodging$7,55312%
  • Food & beverage$10,85317%
  • Education$1370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,137 in reported general payments places this provider in the 95th percentile of 74 gynecology providers in Massachusetts.

See all gynecology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$545,622
Medicare patients
704
Services billed
15,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron457$380,183
MyrbetriqMirabegron40$36,725
Estradiol240$20,434
PremarinEstrogens, Conjugated37$16,663
Clobetasol Propionate86$4,919
Solifenacin Succinate45$4,152
Fosfomycin Tromethamine22$3,687
Methenamine Hippurate59$2,355
YuvafemEstradiol23$2,314
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst141$1,727
Trospium Chloride21$1,181
Cephalexin77$555
Desmopressin Acetate13$221
NitrofurantoinNitrofurantoin Macrocrystal14$207
Ibuprofen59$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$368$380,183457 claims
Astellas Pharma US IncMyrbetriq$649$36,72540 claims
PfizerPremarin$374$16,66337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 74 gynecology providers in Massachusetts.

Other gynecology in New York

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →